- Oops!Something went wrong.Please try again later.
Shares of Icon (NASDAQ:ICLR) were unchanged after the company reported Q2 results.
Earnings per share fell 28.99% year over year to $1.20, which beat the estimate of $1.10.
Revenue of $620,228,000 decreased by 10.78% from the same period last year, which beat the estimate of $598,770,000.
Q3 EPS expected between $6.00 and $6.50.
Q3 revenue expected between $2,650,000,000 and $2,750,000,000.
Company's 52-week high was at $194.17
Company's 52-week low was at $104.28
Price action over last quarter: Up 27.64%
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.
See more from Benzinga
© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.